Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2015
Reporting Period: The filing reports on corporate governance amendments effective February 26, 2015.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
Effective February 26, 2015, the company amended its Certificate of Incorporation to:
- Remove the specific board size provision.
- Update the classified board provision to establish a staggered board structure.
Board Structure Details:
- Directors are divided into three classes (Class I, Class II, and Class III).
- Each class consists of up to three directors.
- Directors serve three-year terms ending on the date of the third annual meeting following their election.
- Initial terms were set based on the 2013 annual stockholders meeting (12, 24, and 36 months respectively) to implement the staggered structure.
- Future board size is governed by the bylaws, allowing a range of 1 to 9 directors as designated by the Board.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a procedural filing regarding corporate charter amendments.
Key Facts for Investor Verification
- Verify the implementation of the staggered board structure and its impact on shareholder voting rights and director elections.
- Confirm the current number of directors appointed to each class (I, II, and III) as of the filing date.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional provisions not summarized in the 8-K.